| Name | Title | Contact Details |
|---|
Automated Group Administration, Inc. is a Fort Wayne, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Argentum is the leading national trade association serving companies that own, operate, and support professionally managed senior living communities in the United States.
Discover more than you expect at your Center... Preschool, Camp, Fitness, Culture, Community & More
Advanced Excimer Laser-Based Vascular and Dermatological Therapies We are a medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients` quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. We currently manufacture and market two lines of products: DABRA Catheter and Laser is cleared by the U.S. FDA as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, including peripheral artery disease (PAD) and critical limb ischemia (CLI). Pharos Excimer Laser is FDA cleared as a tool used in the treatment of inflammatory skin conditions, including psoriasis, atopic dermatitis, and leukoderma.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.